Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rogaratinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 known ✓ | P11362 | 20/20 | 0.99 |
| ▸ | FGFR3 known ✓ | P22607 | 13/20 | 0.99 |
| ▸ | FGFR4 known ✓ | P22455 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rogaratinib SCHEMBL22288911 | 1.00 | FGFR1 (0.99) | FGFR1FGFR3FGFR4 | |
| Rogaratinib SCHEMBL29542499 | 0.99 | FGFR1 (0.97) | FGFR1FGFR3FGFR4 | |
| Rogaratinib SCHEMBL15023004 | 0.99 | FGFR1 (1.00) | FGFR1FGFR3FGFR4 | |
| Rogaratinib SCHEMBL29358162 | 0.99 | FGFR1 (1.00) | FGFR1FGFR3FGFR4 | |
| Hydrochloric Acid SCHEMBL15023352 | 0.94 | FGFR1 (0.99) | FGFR1FGFR3FGFR4 | |
| SCHEMBL15023375 | 0.94 | FGFR1 (1.00) | FGFR1FGFR3FGFR4 | |
| SCHEMBL15023167 | 0.94 | FGFR1 (1.00) | FGFR1FGFR3FGFR4 | |
| SCHEMBL22315228 | 0.93 | FGFR1 (0.89) | FGFR1FGFR3FGFR4 | |
| SCHEMBL15023243 | 0.93 | FGFR1 (1.00) | FGFR1FGFR3FGFR4 | |
| Hydrochloric Acid SCHEMBL15023385 | 0.93 | FGFR1 (0.88) | FGFR1FGFR3FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019180141-A1 | COMBINATIONS OF ROGARATINIB | BAYER AKTIENGESELLSCHAFT (DE) | 2019-09-26 | — | — | WO | claimed |
| US-20180055851-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-01 | — | — | US | claimed |
| EP-3268490-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | Bayer Pharma Aktiengesellschaft (DE) | 2018-01-17 | — | — | EP | claimed |
| WO-2016142312-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | WO | claimed |
| US-20220153745-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2022-05-19 | — | — | US | disclosed |
| EP-3268490-B1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | Bayer Pharma AG (DE) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019180141-A1 | COMBINATIONS OF ROGARATINIB | BAYER AKTIENGESELLSCHAFT (DE) | 2019-09-26 | — | — | WO | disclosed |
| US-10406162-B2 | Substituted 2,3-dihydroimidazo[1,2-C]quinazoline-containing combinations | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-09-10 | — | — | US | disclosed |
| US-20190016724-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-01-17 | — | — | US | disclosed |
| US-20180055851-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-01 | — | — | US | disclosed |
| EP-3268490-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | Bayer Pharma Aktiengesellschaft (DE) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016142312-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | WO | disclosed |
| EP-2791140-B1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | Bayer Pharma AG (DE) | 2016-06-15 | — | — | EP | disclosed |
| US-9206184-B2 | Disubstituted benzothienyl-pyrrolotriazines and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-08 | — | — | US | disclosed |
| US-20140336173-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20130158000-A1 | Disubstituted benzothienyl-pyrrolotriazines and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153745-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | NR5A2, FGFR1, FGFR3 | FGFR1 2/4885FGFR3 3/4885FGFR4 7/4885 |
| US-10406162-B2 | Substituted 2,3-dihydroimidazo[1,2-C]quinazoline-containing combinations | PIK3R5, FGFR3, PIK3R4 | FGFR1 5/4885FGFR3 2/4885FGFR4 11/4885 |
| US-20130158000-A1 | Disubstituted benzothienyl-pyrrolotriazines and uses thereof | STK25, CDK5, JAK2 | FGFR1 216/4885FGFR3 580/4885FGFR4 581/4885 |
| US-20180055851-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | PIK3R5, PIK3R4, PIK3R1 | FGFR1 11/4885FGFR3 4/4885FGFR4 15/4885 |
| US-20140336173-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | NR5A2, NR2C2, FGFR1 | FGFR1 3/4885FGFR3 4/4885FGFR4 11/4885 |
| US-20190016724-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | FGFR1, NR5A2, FGFR3 | FGFR1 1/4885FGFR3 3/4885FGFR4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.